Alector (ALEC) Non-Current Deffered Revenue (2018 - 2026)
Alector (ALEC) reported Non-Current Deffered Revenue of $162.9 million for Q1 2026, down 4.37% year-over-year from $170.3 million in Q1 2025, and down 1.02% on a QoQ basis from $164.5 million in Q4 2025.
Alector (ALEC) has 9 years of Non-Current Deffered Revenue data on file, last reported at $162.9 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 4.37% year-over-year to $162.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $162.9 million (down 4.37% YoY) and the FY2025 annual result came in at $164.5 million, down 4.43% from the prior year.
- Non-Current Deffered Revenue eased to $162.9 million in Q1 2026 per ALEC's latest filing, from $164.5 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $505.1 million in Q1 2022 and bottomed at $162.9 million in Q1 2026.
- The 5-year median for Non-Current Deffered Revenue is $204.6 million (2024), against an average of $262.9 million.
- The widest annual swing landed in 2022, when Non-Current Deffered Revenue surged 378.83%; it then plunged 52.54% in 2024.
- Tracing ALEC's Non-Current Deffered Revenue over 5 years: stood at $443.4 million in 2022, then tumbled by 52.44% to $210.8 million in 2023, then dropped by 18.34% to $172.2 million in 2024, then dropped by 4.43% to $164.5 million in 2025, then retreated by 1.02% to $162.9 million in 2026.
- Per Business Quant, the three latest ALEC Non-Current Deffered Revenue figures stand at $162.9 million (Q1 2026), $164.5 million (Q4 2025), and $167.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Alector | 238.87 Mn | 32.36 Mn | - | 162.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.87 Mn |
| Dec 31, 2025 | 164.54 Mn |
| Sep 30, 2025 | 167.27 Mn |
| Jun 30, 2025 | 168.87 Mn |
| Mar 31, 2025 | 170.31 Mn |
| Dec 31, 2024 | 172.17 Mn |
| Sep 30, 2024 | 192.78 Mn |
| Jun 30, 2024 | 199.58 Mn |
| Mar 31, 2024 | 204.58 Mn |
| Dec 31, 2023 | 210.85 Mn |
| Sep 30, 2023 | 229.85 Mn |
| Jun 30, 2023 | 245.34 Mn |
| Mar 31, 2023 | 431.08 Mn |
| Dec 31, 2022 | 443.37 Mn |
| Sep 30, 2022 | 386.36 Mn |
| Jun 30, 2022 | 413.90 Mn |
| Mar 31, 2022 | 505.13 Mn |
| Dec 31, 2021 | 334.42 Mn |
| Sep 30, 2021 | 344.53 Mn |
| Jun 30, 2021 | 96.21 Mn |
| Mar 31, 2021 | 105.49 Mn |
| Dec 31, 2020 | 108.42 Mn |
| Sep 30, 2020 | 110.56 Mn |
| Jun 30, 2020 | 110.32 Mn |
| Mar 31, 2020 | 114.14 Mn |
| Dec 31, 2019 | 123.24 Mn |
| Sep 30, 2019 | 129.88 Mn |
| Jun 30, 2019 | 121.23 Mn |
| Mar 31, 2019 | 130.49 Mn |
| Dec 31, 2018 | 139.72 Mn |